We use cookies to ensure you get the best experience on our website. Learn more about our privacy policy.
Attention
This is an external link. Click “OK” to continue.
Meet our Board of Directors
Antibe’s Board of Directors comprises experts in governance, capital markets, financial reporting and control, risk management, pharmacology and large pharma transactions. Learn about our corporate governance.
|
President, CEO and Chairman Kintara Therapeutics, USA Prior to taking on his executive role at Kintara (Nasdaq), Robert was CFO of San Diego-based Heron Pharmaceuticals, a Nasdaq-listed commercial stage drug developer with a pipeline of acute pain therapeutics. During his tenure at Heron, the company raised more than $650 million and launched its second commercial drug product. His career in the biotechnology sector began in 1997 at Arena Pharmaceuticals, where he rose to become CFO. While at Arena, he was involved with its IPO and financings raising more than $1.5 billion. For 10 years until 2020, Robert was a member of the Small Business Advisory Committee of the Financial Accounting Standards Board (FASB). Robert is a member of the boards of ASLAN Pharmaceuticals (Nasdaq) and privately held FibroBiologics. |
BBA St. Bonaventure University, USA Robert is a founding board member of Day for Change, which has funded charities serving underprivileged and abused children in the San Diego area for 20 years.
|
“It’s a great time to work with Antibe’s impressive team to capture the full potential of a uniquely promising drug pipeline and platform.”
|
Emeritus Professor, Pharmacology William Harvey Research Institute, Queen Mary University, UK Rod has spent much of his career researching inflammation and anti-inflammatory drugs. He was a member of the original group that demonstrated the mechanism of action of NSAIDs. He has also made significant advances in understanding how the glucocorticoids and cromone drugs produce their anti-inflammatory and anti-allergic actions. He is the former President of the British Pharmacological Society. Rod has published more than 400 papers and is a co-author of a best-selling pharmacology textbook. |
PhD Pharmacology University of London, UK Fellow Rod is a recipient of several awards, including the William Withering Prize of the Royal College of Physicians, the Wellcome Gold Medal of the British Pharmacological Society, and the Lifetime Achievement Award of the International Association of Inflammation Societies.
|
“I believe that Antibe has made a landmark advance towards a safer treatment for inflammation.”
Chief Business Officer Knight Therapeutics, Canada | MBA University of Ottawa, Canada
Amal has led due diligence, deal structuring and negotiations for more than 20 transactions, with a combined deal value of $500M. |
“The treatment of pain continues to pose a great challenge as there is a high unmet need for safe and effective pain therapies.”
|
Having first met him in university, Antibe’s founder, John Wallace, reconnected with Dan nearly 30 years later, seeking to tap his talent for leading senior teams in building best-in-class ventures. |
JD Queen’s University, Canada Dan’s leadership experience began with eight years as a military pilot, principally as an air rescue captain.
|
“We think we’ve solved one of the significant, long-standing medical problems of our time.”
|
Vice Chairman (retired) Mastercard Incorporated, USA
Until 2020, he was Vice Chairman of MasterCard Incorporated, where he was involved in various public-private partnership initiatives. He previously served as President of International Markets, overseeing MasterCard’s business in 210 countries. |
MBA Schulich School of Business, York University, Canada Walt is the founder of Mastercard’s Center for Inclusive Growth, and has chaired the Centre for Social Impact at Queen’s University, and Convergence Finance. He has been a board member of Save the Children Canada, Big Brothers Big Sisters of Canada, the Royal Conservatory of Music, and the Sunnybrook Hospital Foundation.
|
“Better medicines for pain promise a better world for billions of people.”
|
Senior Financial Executive Jennifer is a senior financial executive with a considerable breadth of experience in the biotechnology sector, as an analyst, portfolio manager, information provider and expert in corporate communications and investor relations. She is former Chief Financial Officer of Codex DNA, Inc. Beginning her career as a healthcare equity analyst, Jennifer transitioned to managing biopharmaceutical-focused investment funds. She subsequently founded Laurient LLC, an independent equity research and competitive intelligence platform analyzing publicly traded biopharmaceutical companies. |
Master of Health Administration (MHA) Cornell University, USA Jennifer managed biopharmaceutical-focused investment funds for Morgan Stanley Dean Witter Advisors, Amerindo Investment Advisors and latterly at Franklin Templeton, where she co-managed the Franklin Biotechnology Discovery Fund.
|
“The severe shortcomings of today’s pain medications constitute one of the world’s most pressing medical needs. Patients deserve better. Antibe’s novel drug platform is a promising way forward – I am delighted to be a part of it.”
|
CEO MaRS Discovery District, Canada Yung has built breakthrough companies in mobile analytics and big data, media and entertainment, enterprise software, financial services and pharma. He is CEO of the MaRS Discovery District, the largest urban innovation hub in North America, and Canada’s premiere science and technology innovation ecosystem. Since its inception, the MaRS innovation community has raised over $10.6 billion in capital, generated over $7.1 billion in revenue and currently employs over 22,800 people in the health, cleantech, fintech and platform technologies sectors. He serves on the board directors of OMERS, a leading Canadian institutional investor with $100 billion under management. Yung is a former director of Green Shield Canada, a leading health benefits administrator and one of Canada’s foremost social enterprises in healthcare. |
Entrepreneurial Masters Program Massachusetts Institute of Technology, USA Directors Education Program Rotman School of Management, University of Toronto, Canada Certifications Yung was recognized as one of Canada’s “Top 40 under 40” leaders earlier in his career and as chief executive of one of Canada’s “50 Best Managed Private Companies”.
|
“Antibe ranks amongst the most promising biotech companies that we work with.”
COMMITTEE MEMBERSHIP:
1. Audit Committee
2. Governance and Nomination Committee
3. HR and Compensation Committee